LARGE-ONE: A Prospective, Multicenter, Randomized Controlled Trial of the Use of Drug-coating Balloons(DCB) or Drug-eluting Stents(DES) in the Treatment of Large Diameter Coronary Atherosclerotic Lesions

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

For the treatment of primary large-diameter coronary atherosclerosis through percutaneous coronary intervention (PCI), the use of a drug balloon (DCB) is not inferior to the placement of a drug-eluting stent (Firehawk™ family). \* Large-diameter vessels were defined as vessels with a diameter of ≥3.00 mm and ≤ 4.0mm

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

⁃ CI1. Age of subject 18-75 years old;

⁃ CI2. The subject (or legal guardian) understands and provides written informed consent to the test requirements and treatment procedures prior to performing any specific tests or procedures in the study;

⁃ CI3. The subject is suitable for percutaneous coronary intervention (PCI);

⁃ CI4. The subject had symptomatic coronary artery disease with objective evidence or asymptomatic ischemia;

⁃ CI5. Subject is willing to submit to all subsequent evaluations required by the test protocol

⁃ Angiogragh Inclusion

⁃ AI1. At Maximum 2 target lesions with stenosis ≥50%, located in no more than 2 vessels with a visual reference vessel diameter (RVD) of ≥3.00 mm and ≤4.00 mm;

⁃ AI2. The length of the target lesion must be≤35 mm (visually) and can be covered by one study stent or drug balloon;

⁃ AI3. The first target lesion must be successfully predilated/pretreated without:

• Vascular tears affecting hemodynamics (TIMI blood grade ≤2);

• Coronary dissection classified as D, E and F(ARC);

• Residual stenosis \> 30% after lesion preparation;

⁃ Note: If Type C dissection occurs at lesion predilation/preparation, clinical investigators will determine whether the target lesion can be included based on the comprehensive situation of blood flow and patients risks . Type C dissection will be excluded from the OCT subgroup considering the risk of dissection extension for OCT operation.

⁃ AI4. The anatomical conditions of the coronary artery were appropriate, and the study instrument could be transported to the appropriate location of the target lesion.

Locations
Other Locations
China
Jining Medical University Affiliated Hospital
RECRUITING
Jining
Contact Information
Primary
Lijun Gan, doctoral
13792336453@163.com
18505370616
Time Frame
Start Date: 2022-12-30
Estimated Completion Date: 2026-01
Participants
Target number of participants: 134
Treatments
Experimental: DCB ARM
patients with large primary coronary artery lesions (3.0mm≤ vessel diameter ≤4.0mm, lesion length ≤35mm).
Active_comparator: DES ARM
patients with large primary coronary artery lesions (3.0mm≤ vessel diameter ≤4.0mm, lesion length ≤35mm).
Sponsors
Leads: Shanghai MicroPort Medical (Group) Co., Ltd.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials